Tenax Therapeutics (NASDAQ:TENX) Stock Rating Raised to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Tenax Therapeutics (NASDAQ:TENX) from a strong sell rating to a sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

TENX has been the topic of several other research reports. Roth Capital set a $5.00 price objective on Tenax Therapeutics in a research report on Monday, August 10th. Evercore lowered shares of Tenax Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective on the stock. in a research report on Tuesday, August 11th. William Blair cut shares of Tenax Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, August 10th. Guggenheim downgraded Tenax Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, August 31st. Finally, UBS Group cut Tenax Therapeutics to a “neutral” rating in a research note on Monday, August 31st. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Tenax Therapeutics has an average rating of “Hold” and an average price target of $14.00.

Tenax Therapeutics Stock Performance

Tenax Therapeutics stock opened at $1.69 on Friday. Tenax Therapeutics has a fifty-two week low of $1.31 and a fifty-two week high of $19.40. The firm’s 50-day simple moving average is $1.81 and its 200 day simple moving average is $9.74. The stock has a market cap of $63.24 million, a PE ratio of -1.22 and a beta of 0.99.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.04. As a group, analysts predict that Tenax Therapeutics will post -1.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Adar1 Capital Management, Llc bought 900,000 shares of Tenax Therapeutics stock in a transaction on Thursday, September 3rd. The stock was acquired at an average price of $1.78 per share, with a total value of $1,602,000.00. Following the acquisition, the insider directly owned 6,524,151 shares of the company’s stock, valued at $11,612,988.78. This represents a 16.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders bought 3,682,899 shares of company stock valued at $6,388,279. 10.81% of the stock is owned by company insiders.

Institutional Trading of Tenax Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TENX. Bank of America Corp DE increased its holdings in shares of Tenax Therapeutics by 391.2% in the first quarter. Bank of America Corp DE now owns 18,569 shares of the specialty pharmaceutical company’s stock worth $297,000 after purchasing an additional 14,789 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Tenax Therapeutics by 1,005.2% during the third quarter. Russell Investments Group Ltd. now owns 22,667 shares of the specialty pharmaceutical company’s stock worth $43,000 after purchasing an additional 20,616 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Tenax Therapeutics during the first quarter worth about $501,000. Squarepoint Ops LLC purchased a new position in shares of Tenax Therapeutics during the second quarter worth about $485,000. Finally, Alps Advisors Inc. increased its position in shares of Tenax Therapeutics by 82.8% in the third quarter. Alps Advisors Inc. now owns 49,225 shares of the specialty pharmaceutical company’s stock worth $93,000 after purchasing an additional 22,301 shares during the last quarter. Institutional investors own 1.67% of the company’s stock.

Key Headlines Impacting Tenax Therapeutics

Here are the key news stories impacting Tenax Therapeutics this week:

• Positive Sentiment: Tenax reported a third-quarter loss of $0.31 per share, narrower than analysts’ expected $0.35 loss. The company also said analyses of its LEVEL trial informed a predictive-enrichment strategy for the amended LEVEL-2 protocol, and that it has been granted a Type C meeting with the FDA. Tenax reports third-quarter results and corporate update
• Neutral Sentiment: The class action’s lead-plaintiff deadline is December 28, 2026. The court has not established that the allegations are true. Johnson Fistel investor alert
• Negative Sentiment: Investors’ attention is focused on a securities class action covering purchases from November 13, 2023, through August 7, 2026. The complaint alleges Tenax and certain executives made misleading statements about TNX-103’s clinical prospects; one notice says the company raised $134 million before its Phase 3 LEVEL trial missed its primary endpoint. The litigation creates uncertainty and could add legal costs, although the claims remain allegations. TENX shareholder alert and lawsuit allegations

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.